Abion
web2Abion is a South Korean biotechnology company developing precision-oncology drug candidates, in...
About
Abion is a South Korean biotechnology company developing precision-oncology drug candidates, including small molecules and antibody-based therapies, alongside biomarker-guided strategies for cancer treatment. Its pipeline includes vabametkib, also known as ABN401, an oral c-MET inhibitor being studied in non-small cell lung cancer with MET exon 14 skipping or amplification. The company is also developing antibodies against claudin-3 and TROP2-directed antibody–interferon beta fusion programs, with work spanning discovery, preclinical development and clinical studies. Abion is listed on South Korea’s KOSDAQ market under code 203400, and its published portfolio centers on oncology research and development.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Abion profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy